Using the overall survival (OS), disease free survival (DFS) and progression free survival (PFS), as well as associated toxicity, the purpose of this work was to evaluate the effectiveness of HDS followed by ASCT as salvage therapy. A retrospective analysis was performed of 106 patients with high grade non-Hodgkin lymphoma receiving HDS followed by ASCT, between 1998 and 2006. Median age was 45 years (Range: 8-65), with 66 (62%) men. Histopathological classification was: 78% DLBCL patients, 12% T and anaplastic and 9% Mantle cell lymphomas; 87% had B cell and 12% T cell lymphomas; 83% were stage III-IV (Ann Arbor Staging), 63% had B symptoms, 32% had bone marrow involvement, 62% bulky disease and 42% high-intermediate or high risk IPI. After HDCY, 9 patients died, 7 from toxicity and 2 from sepsis. Eighty patients underwent ASCT, 47% were in complete remission (CR) and 15% died, all from toxicity. Their OS was 45% over 8 years. During the follow-up, another 35 patients died [4 CR, 1 partial response (PR), 2 relapsed disease (RD) and 28 disease progression (DP)], 11 (31%) had not performed ASCT. OS was 37%; DFS was 49% and PFS 28%. OS by diagnosis was 42% for DLBCL, 40% for T-cell (8 y) and 20% for Mantle Cell (6 y) (P=NS). OS by B symptom patients was 22% vs. 58% (P=0.002) and PFS was 23% vs. 37% (P=0.03). Patients who achieved CR after HDCY (38) had significantly better OS and PFS (38% and 17%) than patients who remained in DP (P<0.0001). Cox Regression demonstrated therapeutic lines before HDCY (Relative risk - RR = 1.41; CI 95%: 1.04-1.90; P= 0.02) and PD both before (RR = 2.70; CI 95%: 1.49-4.91, P<0.001) and after HDCY (RR = 5.38; 95% CI: 2.93-9.87; P<0.0001). Conclusions: Our study suggests HDS is an efficient treatment to improve status and to reduce tumoral burden. Regardless of toxicity-related mortality it is feasible, especially considering the poor prognosis of patients.31SUPPL. 2914Verdonck, L.F., Dekker, A.W., de Gast, G.C., van Kempen, M.L., Lokhorst, H.M., Nieuwenhuis, H.K., Salvage therapy with ProMACE-MOPP followed by intensive chemoradiotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who failed to respond to first-line CHOP (1992) J Clin Oncol., 10 (12), pp. 1949-54Vose, J.M., Zhang, M.J., Rowlings, P.A., Lazarus, H.M., Bolwell, B.J., Freytes, C.O., Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry (2001) J Clin Oncol, 19 (2), pp. 406-13Kewalramani, T., Zelenetz, A.D., Hedrick, E.E., Donnelly, G.B., Hunte, S., Priovolos, A.C., High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: An intention-to-treat analysis (2000) Blood, 96 (7), pp. 2399-404Josting, A., Reiser, M., Rueffer, U., Salzberger, B., Diehl, V., Engert, A., Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: Is there a chance for cure? (2000) J Clin Oncol., 18 (2), pp. 332-9Santini, G., Coser, P., Congiu, A.M., Salvagno, L., de Souza, C., Sertoli, M.R., VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: A study by the non-Hodgkin's Lymphoma Co-operative Study Group (2000) Haematologica, 85 (2), pp. 160-6Phillips, G.L., Wolff, S.N., Herzig, R.H., Lazarus, H.M., Fay, J.W., Lin, H.S., Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation (1989) Blood, 73 (8), pp. 2086-92Bierman, P.J., Bagin, R.G., Jagannath, S., Vose, J.M., Spitzer, G., Kessinger, A., High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long-term follow-up in 128 patients (1993) Ann Oncol, 4 (9), pp. 767-73Moskowitz, C.H., Nimer, S.D., Zelenetz, A.D., Trippett, T., Hedrick, E.E., Filippa, D.A., A 2-step comprehensive high-dose chemo-radiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model (2001) Blood, 97 (3), pp. 616-23Gianni, A.M., Siena, S., Bregni, M., Lombardi, F., Gandola, L., Di Nicola, M., High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease--a 6-year update (1993) Ann Oncol, 4 (10), pp. 889-91Stella, C.C., Cazzola, M., de Fabritiis, P., de Vincentiis, A., Gianni, A.M., Lanza, F., CD34-positive cells: Biology and clinical relevance (1995) Haematologica, 80 (4), pp. 367-87Tarella, C., Caracciolo, D., Corradini, P., Zallio, F., Ladetto, M., Cuttica, A., Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft (2000) Leukemia, 14 (4), pp. 740-7Vitolo, U., Liberati, A.M., Lambertenghi Deliliers, G., A multicenter randomized trial by Italian Lymphoma Intergroup (ILI) comparing high dose chemotherapy (HDS) with autologous stem cell transplantation (ASCT) vs. intensified chemotherapy MegaCEOP in high risk diffuse large cell lymphoma (DLCL): No difference in outcome and toxicity (2001) Blood, 98, pp. 725aCaracciolo, D., Gavarotti, P., Aglietta, M., Bondesan, P., Falda, M., Gallo, E., High-dose sequential (HDS) chemotherapy with blood and marrow cell autograft as salvage treatment in very poor prognosis, relapsed non-Hodgkin's lymphoma (1993) Bone Marrow Transplant, 12 (6), pp. 621-5Cortelazzo, S., Rambaldi, A., Rossi, A., Oldani, E., Ghielmini, M., Benedetti, F., Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma (2001) Br J Haematol, 114 (2), pp. 333-41Josting, A., Sieniawski, M., Glossmann, J.P., Staak, O., Nogova, L., Peters, N., High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: Results of a multicenter phase II study (2005) Ann Oncol., 16 (8), pp. 1359-65Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues (2000) Hematol J., 1 (1), pp. 53-66. , Report of the Clinical Advisory Committee meeting--Airlie House, Virginia, NovemberCarbone, P.P., Kaplan, H.S., Musshoff, K., Smithers, D.W., Tubiana, M., Report of the Committee on Hodgkin's Disease Staging Classification (1971) Cancer Res, 31 (11), pp. 1860-1(1993) The International Non-Hodgkin's Lymphoma Prognostic Factors N Engl J Med, 329 (14), pp. 987-94. , A predictive model for aggressive non-Hodgkin's lymphomade Souza, C.A., Vassallo, J., Lorand-Metze, I., Hodgkin's disease in Brazil: A clinicopathologic study (1997) Haematologica, 82 (1), pp. 127-8Vassallo, J., Metze, K., Traina, F., de Souza, C.A., Lorand-Metze, I., Expression of Epstein-Barr virus in classical Hodgkin's lymphomas in Brazilian adult patients (2001) Haematologica, 86 (11), pp. 1227-8Hallack Neto, A.E., Pereira, J., Beitler, B., Chamone, D.A., Llacer, P.D., Dulley, F.L., Results of CHOP chemotherapy for diffuse large B-cell lymphoma (2006) Braz J Med Biol Res., 39 (10), pp. 1315-22. , Oct;, Epub 2006 Aug 22Tarella, C., Cuttica, A., Vitolo, U., Liberati, M., Di Nicola, M., Cortelazzo, S., High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: A multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence (2003) Cancer, 97 (11), pp. 2748-59Sureda, A., Arranz, R., Iriondo, A., Carreras, E., Lahuerta, J.J., García-Conde, J., Autologous stem-cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group (2001) J Clin Oncol, 19 (5), pp. 1395-404Keegan, T.H., Glaser, S.L., Clarke, C.A., Gulley, M.L., Craig, F.E., Digiuseppe, J.A., Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: A population-based study (2005) J Clin Oncol, 23 (30), pp. 7604-13Gianni, A.M., Siena, S., Bregni, M., Lombardi, F., Gandola, L., Valagussa, P., Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease (1991) Ann Oncol, 2 (9), pp. 645-53Josting, A., Rudolph, C., Mapara, M., Glossmann, J.P., Sieniawski, M., Sieber, M., Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: Results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG) (2005) Ann Oncol, 16 (1), pp. 116-23Baldissera, R.C., Aranha, J.F., Oliveira, G.B., Vigorito, A.C., Eid, K.A., Miranda, E.C., High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma (2002) Braz J Med Biol Res, 35 (1), pp. 49-57Tarella, C., Cuttica, A., Caracciolo, D., Zallio, F., Ricca, I., Bergui, L., High-dose sequential (HDS) chemotherapy for high-risk non-Hodgkin's lymphoma: Long-term analysis and future developments (2001) Ann Hematol., 80 (SUPPL. 3), pp. B123-6Norton, L., Simon, R., The Norton-Simon hypothesis revisited (1986) Cancer Treat Rep, 70 (1), pp. 163-9Aleman, B.M., van den Belt-Dusebout, A.W., Klokman, W.J., Van't Veer, M.B., Bartelink, H., van Leeuwen, F.E., Long-term cause-specific mortality of patients treated for Hodgkin's disease (2003) J Clin Oncol, 21 (18), pp. 3431-9Lazarus, H.M., Loberiza Jr, F.R., Zhang, M.J., Armitage, J.O., Ballen, K.K., Bashey, A., Autotransplants for Hodgkin's disease in first relapse or second remission: A report from the autologous blood and marrow transplant registry (ABMTR) (2001) Bone Marrow Transplant, 27 (4), pp. 387-96Wheeler, C., Khurshid, A., Ibrahim, J., Elias, A., Mauch, P., Ault, K., Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV) (2001) Leuk Lymphoma, 40 (5-6), pp. 499-509